Real-life use of bone-targeting agents for bone metastases in France between 2009 and 2018: Results of the OPTIMOS study

Journal of bone oncology 2026 Open access

Read full text
Authors: Cyrille B. Confavreux, Béatrice Bouvard, Nicolas Girard, Pauline Bosco-Levy, Clarisse Marchal, Maëva Nolin, Eric Lehmann, Gaelle Desameric, Manon Belhassen
DOI: 10.1016/j.jbo.2025.100738
Cited by: 3
References: 34

Abstract

• Bone-targeting agents (bisphosphonates, denosumab) reduce skeletal complications and improve quality of life. • Bone-targeting agents should be initiated in bone metastatic patients (ESMO 2020 guidelines). • In real life, less than 10 % of bone metastatic patients did receive bone-targeting agents in France. • Early initiation (

Fields of Study & Subjects

Management of metastatic bone disease Bone health and treatments Prostate Cancer Treatment and Research

Publication details

Journal / source
Journal of bone oncology
Publisher
Elsevier BV
Volume
56
Pages
100738–100738
Publication date
4 January 2026
Language
EN